Peer Review reports
From: Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
| Original Submission | ||
|---|---|---|
| 6 Dec 2021 | Submitted | Original manuscript |
| 25 Dec 2021 | Reviewed | Reviewer Report |
| 28 Jan 2022 | Reviewed | Reviewer Report - Athanasia Papazafiropoulou |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 25 Dec 2021 | Reviewed | Reviewer Report |
| 28 Jan 2022 | Reviewed | Reviewer Report - Athanasia Papazafiropoulou |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 25 Dec 2021 | Reviewed | Reviewer Report |
| 28 Jan 2022 | Reviewed | Reviewer Report - Athanasia Papazafiropoulou |
| Resubmission - Version 4 | ||
| Submitted | Manuscript version 4 | |
| 25 Dec 2021 | Reviewed | Reviewer Report |
| 28 Jan 2022 | Reviewed | Reviewer Report - Athanasia Papazafiropoulou |
| Resubmission - Version 5 | ||
| Submitted | Manuscript version 5 | |
| Publishing | ||
| 28 Mar 2022 | Editorially accepted | |
| 26 Apr 2022 | Article published | 10.1186/s12902-022-01026-2 |
You can find further information about peer review here.